The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma: Subgroup analysis from the phase 3 ETER100 trial.
 
Xinan Sheng
Speakers' Bureau - Astellas Pharma; Junshi Pharmaceuticals; MSD Oncology; Pfizer; RemeGen
 
Pengfei Shen
No Relationships to Disclose
 
Zengjun Wang
No Relationships to Disclose
 
Xiubao Ren
No Relationships to Disclose
 
Yuan Li
No Relationships to Disclose
 
Shusuan Jiang
No Relationships to Disclose
 
Gang Li
No Relationships to Disclose
 
Yu Zeng
No Relationships to Disclose
 
Weijun Qin
No Relationships to Disclose
 
Jin Wu
No Relationships to Disclose
 
Peng Chen
No Relationships to Disclose
 
Fangjian Zhou
No Relationships to Disclose
 
HongQian Guo
No Relationships to Disclose
 
Zhigang Ji
No Relationships to Disclose
 
Yongquan Wang
No Relationships to Disclose
 
Zhisong He
No Relationships to Disclose
 
Benkang Shi
No Relationships to Disclose
 
Lian Liu
No Relationships to Disclose
 
Aiping Zhou
No Relationships to Disclose
 
Jun Guo
Consulting or Advisory Role - Bayer; MSD; Novartis; Oriengene; Pfizer; Roche; Shanghai Junshi BioSciences; Simcere